Implementation of Xpert MTB/RIF for routine point-of-care diagnosis of tuberculosis at the primary care level

Kate Clouse, Liesl Page-Shipp, Heather Dansey, Bridgette Moatlhodi, Lesley Scott, Jean Bassett, Wendy Stevens, Ian Sanne, Annelies Van Rie

Xpert MTB/RIF (Xpert) offers rapid detection of *Mycobacterium tuberculosis* and rifampicin resistance. However, little is known about routine point-of-care (POC) use in high TB/HIV burden settings. We describe our experiences of launching Xpert as the POC, initial diagnostic for all TB suspects at a primary healthcare clinic in Johannesburg, South Africa. Noted important benefits of POC: Xpert were fewer clinic visits, rapid detection of TB and rifampicin resistance, real-time assessment of accompanying household members of new TB cases, and increased staff motivation for TB screening.

While Xpert results are available within 2 hours, actual turnaround time was longer for most patients because of sample preparation time and clinic congestion. Consequently, a GX4 instrument did not result in a 16-test capacity during an 8-hour working day, and some patients did not receive same-day results. Loss to follow-up was an unforeseen challenge, overcome by clinic flow changes, marking of clinic files, documenting patients’ physical description and locating patients in the clinic by cell phone. Staff with high school education successfully performed the assay after minimal training.

Human resource requirements were considerable, with a minimum of 2 staff needed to supervise sputum collection, process sputum, perform assays, and document results for an average of 15 TB suspects daily. POC placement of the instrument transferred logistical responsibilities to the clinic, including quality assurance, maintenance, stock control and cartridge disposal.

POC use of Xpert is feasible at the primary healthcare level but must be accompanied by financial, operational and logistical support.

In December 2010, the WHO endorsed Xpert MTB/RIF (Cepheid, Sunnyvale, CA, USA) as a first-line diagnostic for TB in patients suspected of HIV-associated TB or multidrug-resistant (MDR) TB.1 South Africa, the first country to roll out the assay, opted to place the instruments at centralised microscopy centres and reference laboratories of the National Health Laboratory Service, mainly owing to cost considerations and to allow rapid roll-out.2

Xpert MTB/RIF (Xpert)’s short turnaround time and simplicity raised potential for point-of-care (POC) use.3,4 The motivation for POC technology (be it HIV, CD4 or TB testing) is to provide same-day results, hasten treatment initiation, and avoid loss to follow-up during the diagnostic process. Little is known about POC use of Xpert at primary healthcare level, and operational research is needed before its use at the peripheral level can be recommended.5,6

In July 2011, we launched Xpert as the initial, routine, POC diagnostic for all TB suspects at Witkoppen Health and Welfare Centre, a high-volume (8 500 monthly visits), NGO-operated primary care clinic. The centre serves residents of informal settlement areas within northern Johannesburg that have a high HIV and TB burden.

Human resource requirements

Human resource requirements were greater than anticipated, because the use of Xpert increased the number of TB cases identified and because staff time per TB suspect assessed was higher than expected. While Xpert is in principle a 2-hour test,7 this only refers to the assay turnaround time. Registering clients in the TB suspect register, educating them on providing a quality sputum, adding the buffer, processing the sample, transferring the sample into the cartridge, and transporting the cartridge to the instrument, all require personnel and time. Once the assay is ready, the results must be printed and filed and the patient traced within the clinic and referred to the next clinic service, depending on the Xpert result and reason for visit.

Consequently, while we expected to need 1 full-time employee, we found we needed a minimum of 2 full-time employees to ensure operation of POC Xpert services for an average of 16 TB suspects (range: 7 - 29) daily. The clinic opted to employ 2.5 full-time staff to ensure continuous POC Xpert service: 1 person at the outdoor sputum booth for patient assistance, sample buffering and data entry in the suspect register; 1 in the Xpert instrument room to perform the
Research

assay, communicate results to patients and healthcare workers and capture data in clinic file and TB registers; and a third person at 50% effort for assistance during the busy afternoon period and to cover for lunch breaks and absences. In addition, 1 low-skilled runner carries buffered sputum samples between the outdoor sputum collection booth and the instrument room and traces patients within the clinic.

This ‘POC Xpert team’ was employed in addition to the existing clinic TB team, which consists of 1 part-time physician, 1 full-time nurse and 2 full-time auxiliary nurses. Specialised skills were not required, as staff with high school education and no formal laboratory training performed the Xpert assay after 2 days of training.

Instrument requirements

According to the WHO, the four-module Xpert instrument has a capacity of 15 - 20 tests per working day. While this is probably a correct estimate for instruments placed in a laboratory, 2 four-module instruments were required to process an average of 15 samples daily at POC. Even though the clinic operates 8 hours daily, the first sputum sample is only available 2 - 3 hours after the first TB suspect arrives at the clinic, as clients proceed through several administrative and care steps before sputum is collected. The last time a cartridge can be loaded and provide a same-day result is 2 or preferably 3 hours before the clinic closes. Tests for patients who present late in the day are run overnight and results are available the following day. In addition, tests resulting in errors or invalid results need to be repeated. We observed an error or invalid rate of 3.4%, consistent with the 2.4 - 5.9% observed elsewhere.

Infrastructure requirements

TB testing at POC, outside of the laboratory, requires emphasis on infection control and biosafety. An outdoor sputum booth was constructed to provide adequate ventilation, and this is where sputum collection is performed and the Xpert buffer added. Clinic staff are instructed to wear N-95 masks when collecting and buffering sputum, and when communicating face-to-face with TB suspects. New TB cases are asked to wear surgical masks. Conditions for instrument operation within the clinic were also optimised, ensuring a temperature <30°C, stable electrical supply, connection of the 2 instruments to 1 computer, security measures against theft, and adequate storage space for the cartridges.

Changing the clinic flow and optimising patient retention

In contrast to our expectations, many patients initially failed to receive their Xpert result because they had left the clinic or were untraceable within the clinic 2 hours after the cartridge was placed in the instrument. To overcome this problem many interventions requiring co-operation from the entire clinic have been implemented.

First, a paper slip identifying the TB suspect as receiving an Xpert assay is stapled to the outside of the clinic file and only removed once the patient receives the result. This allows the patient to attend other clinic services while the assay is running, and prevents the clinic from unknowingly checking out the patient before they receive their results. It also serves to alert the clinician that the patient has been identified as a TB suspect and is currently awaiting Xpert results. Second, the TB suspect’s cell phone number is recorded (when available) and the number is tested on the spot to ensure it is correct and the phone is turned on. When the test is completed, a text message is sent: ‘Your TB results are ready. Please come to the TB Room.’ Third, a physical description of each TB suspect is recorded, including the colour of clothing worn. When the TB suspect cannot be reached by phone, runners are deployed to help locate patients in the clinic using this description.

Since these measures were implemented, TB suspects have received their test result on the same day, except for those who need to leave the clinic for work purposes and those who provide a sputum sample <2 hours before the clinic closes.

The aim of rapid POC technology is to receive a same-day test result and to act upon it in real-time. When diagnosis is based on smear microscopy, TB suspects provide a sputum sample and come back a few days later. At the second visit, they arrive in the morning and have results ready in their file, and the nurse or clinician can start TB treatment immediately. In contrast, when using Xpert at POC, new cases of TB are identified throughout the day. Staff must therefore be ready to register a new case and initiate treatment at any time, even at the end of the workday.

Furthermore, when provided with Xpert at POC, TB suspects continue their clinic visit while the sample is being processed. However, the results of the Xpert assay may not yet be ready, creating the need for 2 consultations on the same day, once before and once after the Xpert results are available. Since the vast majority of TB suspects are Xpert negative, the clinic opted to presumptively manage TB suspects as Xpert negative and schedule a follow-up visit 1 week later. Consequently, only clients with a positive Xpert result may need to be seen twice by a healthcare worker on a single day or traced to begin TB treatment.

Shifting responsibilities from laboratory to clinic

Positioning Xpert instruments at POC in the clinic has management and cost implications beyond the purchase of the instrument and cartridges required for processing samples. Increased overhead and management costs include instrument insurance, decentralised billing, cartridge procurement and stock control, and data management to ensure results are linked to a national TB database. POC laboratories also require consistent electricity, regular maintenance and calibration of the instruments, staff training, certification, and participation in external quality assurance programmes.

Anticipated and unanticipated benefits of POC Xpert

As expected, placing Xpert at POC resulted in increased case detection, same-day treatment initiation in over 80% of new cases, and knowledge of the M. tuberculosis strain’s susceptibility to rifampicin on the day that treatment is started.

In addition, we discovered some unanticipated benefits. Clinic staff were enthusiastic about the possibility of a same-day result, which increased their motivation to identify TB suspects. Clinicians especially valued the ability to rapidly assess rifampicin resistance among patients not responding to treatment. Awareness of on-site rapid TB testing led clinic staff to request a TB test for themselves when symptomatic. Additionally, the same-day availability of results enabled real-time TB contact identification when a new case was accompanied by a partner or relatives.

Conclusion

While our results were overwhelmingly positive, our experiences highlight that the infrastructure, instrument and human resource
Determinants of mortality in Nigerian children with severe anaemia

Samuel Adegoke, Adenike Ayansanwo, Issac Oluwayemi, John Okeniyi

Background. Severe anaemia (haemoglobin concentration <50 g/l) is a major cause of paediatric hospital admissions and deaths in the tropics.

Objectives. To examine the pattern and predictors of mortality among severely anaemic children.

Methods. A prospective cross-sectional study was conducted among children with severe anaemia at the Children’s Emergency Room of the University Teaching Hospital, Ado-Ekiti, Nigeria. Socio-demographic characteristics, clinical features, laboratory findings and co-morbidities of the survivors and those who died were compared by logistic regression analysis.

Results. Of the 1 735 children admitted, 311 (17.9%) had severe anaemia, with a case-fatality rate of 9.3%. The presence of respiratory distress (95% confidence interval (CI) 2.1 - 3.6, \( p = 0.031 \)); acidosis (95% CI 1.8 - 2.7, \( p = 0.010 \)); coma (95% CI 0.1 - 0.3, \( p = 0.001 \)); hypotension (95% CI 2.0 - 4.2, \( p = 0.020 \)); and bacteraemia (95% CI 3.1 - 3.9, \( p = 0.008 \)) were the significant independent predictors of death with regression analysis.

Conclusion. Early recognition with prompt and appropriate anticipatory intervention is essential to reduce mortality from severe anaemia.

Accepted 16 August 2012.

Severe anaemia is a major cause of paediatric hospital admissions and deaths in many African countries, with a hospital prevalence of 10 - 30% and case fatality rates between 4 and 10%.\(^1,2\) Anaemia, in which blood oxygen carrying capacity is reduced, is characterised by a low haemoglobin concentration.\(^3\) The World Health Organization (WHO) defined severe anaemia in patients with malaria as a haemoglobin concentration less than 50 g/l.\(^4\) Anaemia becomes life-threatening when affected individuals develop complications such as heart failure, metabolic acidosis and hypoxic encephalopathy.\(^5\)

Severe falciparum malaria remains the leading cause of paediatric anaemia in sub-Saharan Africa.\(^6,7\) Anaemia may develop in children already debilitated by other conditions such as nutritional deficiencies, bacteraemia, human immunodeficiency viral (HIV) infections, haemoglobinopathy, glucose-6-phosphate dehydrogenase (G6PD) deficiency, hookworm infestation and leukaemia. In most cases, these factors tend to co-exist.\(^1\)

Severe anaemia-related deaths continue to occur in many centres in the tropics, even where blood transfusion services are readily available.\(^8\) To limit this mortality, we studied children admitted with severe anaemia in a newly established tertiary health centre.

References